Limited Clinical Insight Poses Barrier to Optimal NHL Treatment: Andrew Evens, DO
Clinical approaches to non-Hodgkin lymphoma in younger and older patient groups generally do not differ, according to Andrew Evens, DO, but he emphasized the need for deeper clinical insights into potential biologic differences in younger oncology patients.
The Value of Newborn Screening for DMD: Barry Byrne, MD, PhD
Barry Byrne, MD, PhD, Powell Gene Therapy Center at the University of Florida, discusses gene therapy considerations for pediatric patients and how newborn screening can influence outcomes for patients with Duchenne muscular dystrophy (DMD).
Building Community and Advancing Care at MDA 2025
One of the major highlights of the Muscular Dystrophy Association (MDA) Clinical & Scientific Conference is that invaluable networking opportunities can help clinicians elevate their own best practices.
Shaping Gene Therapy Approaches in Neuromuscular Disease
Adeno-associated virus (AAV)–mediated gene therapy was one of the focal points of this year's Muscular Dystrophy Association conference. Here, Barry Byrne, MD, PhD, University of Florida, speaks to the novel development of AAV gene therapy and its mechanism of action.
2025 GPBCH Employer Symposia Set to Address Cardiovascular, MSK Challenges
Tom Belmont, president and CEO, Greater Philadelphia Business Coalition on Health (GPBCH) previews the upcoming employer symposia, which seeks to help employers navigate solutions for the management and prevention of cardiovascular and musculoskeletal disease.
Atezolizumab, Immunogenic Chemotherapy Combination Shows Promise for DLBCL Treatment
An early pilot trial suggests that combining atezolizumab (tecectriq) with rituximab (Rituxan), gemcitabine (gemzar) and oxaliplatin (eloxatin; GemOx; R-GemOx+Atezo) could be a well-tolerated and effective treatment option in non-Hodgkin lymphoma.
Advances in Gene Therapy, Neuroregeneration at the Forefront of MDA 2025
Look ahead to this year's Muscular Dystrophy Association (MDA) meeting, which will feature discussions on the latest gene therapies, clinical trial data, policy considerations, and more in the realm of neuromuscular disease.